Appendix Table 10.
Outcome by Table | OR Associated With CAD (95% CI) |
|
---|---|---|
Original Analysis With Potential Unmeasured Confounding |
Sensitivity Analysis Accounting for Unmeasured Confounder |
|
Table 1 | ||
Any breast cancer | 1.04 (1.01–1.06) | 1.00 (0.98–1.03) |
Invasive breast cancer | 1.00 (0.97–1.03) | 0.96 (0.95–0.99) |
Stage I invasive | 1.06 (1.03–1.10) | 1.03 (1.00–1.07) |
Stages II–IV invasive | 0.92 (0.87–0.96) | 0.89 (0.85–0.93) |
DCIS | 1.17 (1.11–1.23) | 1.15 (1.09–1.21) |
Table 4 | ||
Smallest OR: Invasive size <1 cm (vs. ≥1 cm) | 1.10 (1.04–1.16) | 1.08 (1.02–1.14) |
Largest OR: Invasive stage I or II (vs. III or IV) | 1.27 (1.14–1.41) | 1.25 (1.13–1.38) |
Table 5 | ||
Smallest OR: Breast ultrasonography | 1.08 (1.06–1.09) | 1.05 (1.03–1.06) |
Largest OR: Diagnostic mammography | 1.28 (1.27–1.29) | 1.25 (1.24–1.26) |
CAD = computer-aided detection; DCIS = ductal carcinoma in situ; OR = odds ratio.
Sensitivity analyses assume a 10% relative imbalance in the prevalence of unmeasured increased breast density among women who receive screening mammography with CAD compared with women who receive screening without CAD.